文献速递慢性肾脏病肾血管病与高血压

醛固酮与残余心肾风险:病理生理学与新兴治疗策略

Aldosterone and Residual Cardiorenal Risk: Pathophysiology and Emerging Therapeutic Strategies.
PubMed 文献 · Nephrol Dial Transplant · 2026-10-16

本文综述醛固酮及盐皮质激素受体(MR)介导的信号在慢性肾脏病(CKD)残余心肾风险中的作用,区分醛固酮过量与MR激活,提出肾脏病学临床框架,并讨论甾体/非甾体MR拮抗剂、醛固酮合酶抑制剂(ASI)及联合SGLT2抑制剂的治疗策略。

要点

  • CKD中RAS持续激活、钾处理受损等可维持醛固酮暴露和MR激活,导致残余心肾风险。
  • MR拮抗剂(MRA)在特定CKD人群有结局获益,但不应解读为所有患者存在生化醛固酮过量。
  • ASI的心肾结局获益尚未确立,EASi-KIDNEY因独立数据监测委员会审查而提前终止。

核心结论

  • 醛固酮相关和MR介导的信号参与炎症、氧化应激、纤维化、白蛋白尿及进展性心肾损伤,是CKD残余心肾风险的潜在治疗靶点。
  • MRA在特定CKD人群已确立结局获益,而ASI的心肾结局获益尚未确立。

研究设计与样本

  • 综述,检索范围未在原文中报告。

主要发现

  • CKD中RAS持续激活、钾处理受损、Klotho降低、醛固酮清除改变及不完全抑制可维持醛固酮暴露和MR激活。
  • MRA结局试验确立MR信号作为特定CKD人群的治疗靶点。
  • EASi-KIDNEY在独立数据监测委员会审查后提前终止,详细结果待公布。

关键数值与推荐

  • MRA在特定CKD人群已确立结局获益;ASI的心肾结局获益尚未确立。

临床怎么用

  • 提出肾脏病学临床框架,区分已确立的MRA适应证、原发性醛固酮增多症评估以及ASI尚未确立的心肾结局作用。
  • 白蛋白尿可作为损伤下游标志物和治疗反应指标。

局限性

  • EASi-KIDNEY详细结果待公布,ASI心肾结局获益尚未确立。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Aldosterone, the terminal effector of the renin-angiotensin-aldosterone system, regulates sodium retention, potassium excretion, and blood pressure. Beyond these classical effects, aldosterone-associated and mineralocorticoid receptor (MR)-mediated signaling is implicated in inflammation, oxidative stress, fibrosis, albuminuria, and progressive cardiorenal injury, while its synthesis is regulated by factors beyond angiotensin II. This is particularly relevant in chronic kidney disease (CKD), where persistent renin-angiotensin system (RAS) activation, impaired potassium handling, reduced Klotho, altered aldosterone clearance, and incomplete suppression may sustain aldosterone exposure and MR activation despite conventional RAS blockade. These mechanisms may contribute to residual cardiorenal risk despite standard-of-care therapy. Mineralocorticoid receptor antagonist (MRA) outcome trials establish MR signaling as a therapeutic target in defined CKD populations, but therapeutic benefit from MR blockade should not be interpreted as evidence of biochemical aldosterone excess in all treated patients. This review distinguishes aldosterone excess from MR activation and proposes a nephrology-focused clinical framework separating established MRA indications, evaluation for primary aldosteronism, and the unestablished cardiorenal outcome role of aldosterone synthase inhibitors (ASIs). We discuss aldosterone-associated and MR-mediated kidney injury, the cardiorenal axis, albuminuria as a downstream marker of injury and treatment response, and current and emerging therapeutic strategies, including steroidal and non-steroidal MRAs, ASIs, and combinations with SGLT2 inhibitors. Whereas MRA therapy has established outcome benefits in defined CKD populations, cardiorenal outcome benefit from ASIs remains unestablished; EASi-KIDNEY was discontinued early after independent Data Monitoring Committee review, with detailed results pending.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Kanbay M, AlShiab R, Shah E, et al. Aldosterone and Residual Cardiorenal Risk: Pathophysiology and Emerging Therapeutic Strategies. Nephrol Dial Transplant. 2026. PMID: 42886065. doi:10.1093/ndt/gfag243

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。